Tag: GlobeNewswire

Irvine, CA, Nov. 02, 2026 (GLOBE NEWSWIRE) — How do you celebrate 125 years as the original car care brand? If you’re Meguiar’s, you reveal a bounty of 2027 product innovations, unveil six curated cars, and hand out more giveaways than at any time in the last 60 years you’ve been exhibiting at SEMA as a founding partner!

The Meguiar’s brand is rooted in Legacy, Innovation and Passion. Its Legacy spans 125 years at the forefront of car care technology and distribution. During that time, the American company has Innovated more product developments at its California headquarters than most of its competitors combined. They do so because of the shared Passion for car culture; wanting to help proud owners keep their cars in better-than-new condition, inside and out; no matter how challenging the finishes or conditions.

You can learn all about the car reveals, signed posters, and giveaways in the SEMA 2026 section below. But for now, we want to highlight some of the 2027 Meguiar’s Car Care Products.

NEW PRODUCTS FOR 2027

MEGUIAR’S HYBRID CERAMIC LINE
Introduced in 2019, the Hybrid Ceramic family that started it all is undergoing a major reboot with the addition of exciting, all-new items and a bold, fresh look complete with all-new bottles, labels and sprayers. Anchoring the reboot is the addition of Meguiar’s proprietary Tri-Tech Chemistry, which delivers improved performance, surface adhesion and longevity.

Hybrid Ceramic Interior Detailer is one of the first with Tri-Tech Chemistry. It delivers the ease of an interior detailer, but with the improved protection expected from Meguiar’s Hybrid Ceramic products. It sprays on to lightly clean and protect interior surfaces, leaving a durable, non-greasy, matte finish as well as UV-blocking protection, which is important for surfaces like plastic, vinyl, leather, rubber, and electronic screens. And there’s a great Tropical Citrus scent to keep the interior fresh. The Meguiar’s Hybrid Ceramic Interior Detailer has an MSRP of $12.99.

Hybrid Ceramic Prime Coat Sealant also features Tri-Tech Chemistry and delivers the first-ever spray-and-wipe, dry-applied Sealant to the lineup. Its all-new formula combines the ease of spray-and-wipe sealants on clean exterior surfaces, without the need for water. Its Tri-Tech Chemistry ensures 1) maximum adhesion and 2) maximum longevity for up to six months of protection thanks to advanced polymers. And 3) hydrophobic performance that will shed dirt when used as a foundation layer like a dry applied spray wax. Meguiar’s products such as Hybrid Ceramic Wash, Hybrid Ceramic Detailer and Hybrid Ceramic Wet Wax can then be used to maintain the ceramic properties. The Meguiar’s Hybrid Ceramic Prime Coat Sealant has an MSRP of $21.99. 
Other items in the Meguiar’s Hybrid Ceramic range include Wet Wax, Liquid Wax, Wash & Wax, Waterless Wash & Wax, Detailer and Tire Shine. Full details are available at Meguiar’s.

MEGUIAR’S WHOLE CAR AIR RE-FRESHERS
In an expansion to the collection released at SEMA 2025, Meguiar’s is expanding the range of scents available in the Luxury Collection of its Whole Car Air Re-Freshers. New for 2027 is Tokyo Nights; an invigorating blend of lemon, lime and ginger, which provides a sophisticated and refreshing take on the highly popular “JDM Squash” scent.

Meguiar’s Whole Car Air Re-Freshers are a range of easy, one-time use aerosols. When the cannister is set in the car, its contents are released to quickly fight odors and create a fresh scent that lasts for weeks.

Other scents in the Luxury Collection include Stargazer, Dubai Sands, Tropical Rainforest and Island Volcano. Each Meguiar’s Whole Car Air Re-Fresher has an MSRP of $11.99

MEGUIAR’S HANGING AIR RE-FRESHERS
For the first time, Meguiar’s is introducing a collection of Hanging Air Re-Freshers. They come in two groups: Standard Scents, which take the form of the Meguiar’s “M” logo, and can be purchased in three-packs of either New Car, Black Chrome or Ultimate scents.

The second group consists of the Luxury Collection scents, which includes Stargazer, Dubai Sands, Tropical Rainforest, Island Volcano and Tokyo Nights. The Hanging Air Re-Freshers feature vibrant colors and scenic designs specific to each scent.

Care has been taken to ensure none of the Hanging Air Re-Fresher scents are overpowering. It’s estimated the scent will last approximately 2-4 weeks. A Hanging Air Re-Fresher three-pack has an MSRP of $6.99.

Visitors to the Meguiar’s Indoor and Outdoor SEMA Booths will be able to pick up a sample of the new Air Re-Freshers while stocks last.

MEGUIAR’S ACCESSORIES
With a legacy of 125 years in the car care industry, Meguiar’s has a keen sense of what works and what people really need to keep their cars in prime condition. The Meguiar’s Accessories range is proof there’s a finger on the pulse of car enthusiasts. These new products expand the existing range of special items for individual requirements to help get the job done right.

Meguiar’s Quik Clean Sticky Mitt
Picking up stubborn dust, dirt, crumbs and fur across numerous interior surfaces can be a time-consuming task, but the new Quik Clean Sticky Mitt is designed to remove it all by simply pushing the soft, squishy and sticky wash mitt-shaped accessory into hard to reach nooks and crannies.

Packaged in a mini wash bucket, the non-toxic Sticky Mitt is a fun, scented, sticky-stretchy blob, shaped like a miniature microfiber wash mitt. It collects all the dust and dirt from awkward places on hard surfaces and can be quickly washed off afterwards. The mitt is re-usable for more than 20 times and has an MSRP of only $9.99.

Meguiar’s Quik Pet Hair Remover
The Quik Pet Hair Remover has been designed to assist pet owners who want to tackle stubborn pet hair and fur. The versatile tool has four soft silicone blades with both smooth and gently serrated edges that quickly lift embedded hair from carpets, fabric seats, floor mats, and upholstery. The versatile tool can be used by hand or with a slow-speed hand drill. The Quik Pet Hair Remover is intended for fabrics and not recommended for leather, vinyl, suede, etc. The MSRP is $14.99

Meguiar’s Swirl Stopper Bucket Insert
This item definitely qualifies as IYKYK. The Swirl Stopper Bucket Insert has been engineered with a one-way design that keeps dirt and grime at the bottom of your wash bucket, helping to reduce scratches and swirls during car washing. It’s an ingeniously simple device that fits most 3.5-5-gallon wash buckets thanks to the engineered feet and unique profile. The Swirl Stopper also includes an integrated finger slot for easy placement and removal. The MSRP is $9.99.

Meguiar’s Universal Microfiber Applicator Pads
Designed specifically for the smooth application of conditioners, dressings, protectants and coatings, the Universal Applicator Pads are ideal for use on tires, trim, leather, vinyl and paint. And because the premium microfiber applicators are machine washable, they can be used again and again. The MSRP is $12.99 for a pack of four. (Not recommended for use with compounds, polishes or waxes).

MORE TO COME
Our brief introduction is only scratching the surface of what Meguiar’s has in store for 2027. In the coming months, we’ll provide more information on the aforementioned products as well as the following:

• Meguiar’s Hot Shine Black Plastic Restorer – an expansion to the Hot Shine trim restoration line, it quickly restores textured exterior trim without difficult-to-remove residue. The MSRP is $9.99
• Meguiar’s Wipes – the convenient Wipes line is getting a major makeover with new packaging, expanded to 35 wipes in each larger, round container, and all six applications have the same $8.99 MSRP
• Meguiar’s Professional M111 Heavy Hitter Compound Gel – Containing AMP-Ceramic Abrasives, the innovative, all-new M111 gel-based compound delivers the highest level of cut Meguiar’s has ever offered professional body shops and detailers! It’s packaged in a 16oz bottle with an MSRP of $29.99

SEMA 2026

Throughout SEMA week – from opening day on November 3 to public day on November 6 – the Meguiar’s booths will be a hive of activity. The primary focus will be booth # 22357 in Central Hall. That’s where you’ll find displays of all the new 2027 Meguiar’s car care products, as well as car care experts to explain their benefits. Additionally, Meguiar’s will reveal Tony Peressini’s 1956 Ford F-100 GT/FX from Fat Fender Garage alongside TJ Hunt’s Aston Martin Vantage.

The indoor booth will host autograph sessions on the first two days, where visitors can pick up a signed, limited edition poster from TJ Hunt, Dustin Williams and Fat Fender Garage (while available) at these times:

TJ Hunt	Tuesday 2PM	Meguiar’s booth # 22357
Dustin Williams	Wednesday 10AM	Meguiar’s booth # 22357
Fat Fender Garage	Wednesday 2PM	Meguiar’s booth # 22357

Don’t despair if you miss the posters because Meguiar’s will be handing out Anniversary Cookies and Leen Customs Pins as well as Hanging Air Re-Freshers, lanyards, keychains and totes (while available).

The Meguiar’s Outdoor Booth # 80030 will feature the brand’s famous big rig, which will be the backdrop for more new car reveals including the following:

• Dustin Williams’ Spoon Honda S2000 Turbo
• Pierre Chan’s Datsun 240Z Twin-Turbo widebody
• Gary Stell Jr’s multi award-winning 1951 Mercury
• AR Motorwerkz Porsche 911 GT3 RS

Additionally, the same new products will be on display, and the same giveaways will be available to outdoor visitors (while available), with the exception of the signed posters.

### ENDS ###

EDITOR’S NOTE
Images of the 2027 Meguiar’s products are available here: dropbox.com/scl/fo/arcvc61ktnnnxidl90t29/AOEl5iqzvh6CpYZSGSXetQE?rlkey=wstrimuj46puw0vn28zsvzu23&dl=0

Attachments

• Meguiar’s® announces its 2027 Car Care Products
• Meguiar’s® announces its 2027 Car Care Products

CONTACT: Blake Beamish
Meguiar's, Inc
bbeamish@meguiars.com

Irvine, CA, Nov. 02, 2026 (GLOBE NEWSWIRE) — How do you celebrate 125 years as the original car care brand? If you’re Meguiar’s, you reveal a bounty of 2027 product innovations, unveil six curated cars, and hand out more giveaways than at any time in the last 60 years you’ve been exhibiting at SEMA as a founding partner!

The Meguiar’s brand is rooted in Legacy, Innovation and Passion. Its Legacy spans 125 years at the forefront of car care technology and distribution. During that time, the American company has Innovated more product developments at its California headquarters than most of its competitors combined. They do so because of the shared Passion for car culture; wanting to help proud owners keep their cars in better-than-new condition, inside and out; no matter how challenging the finishes or conditions.

You can learn all about the car reveals, signed posters, and giveaways in the SEMA 2026 section below. But for now, we want to highlight some of the 2027 Meguiar’s Car Care Products.

NEW PRODUCTS FOR 2027

MEGUIAR’S HYBRID CERAMIC LINE
Introduced in 2019, the Hybrid Ceramic family that started it all is undergoing a major reboot with the addition of exciting, all-new items and a bold, fresh look complete with all-new bottles, labels and sprayers. Anchoring the reboot is the addition of Meguiar’s proprietary Tri-Tech Chemistry, which delivers improved performance, surface adhesion and longevity.

Hybrid Ceramic Interior Detailer is one of the first with Tri-Tech Chemistry. It delivers the ease of an interior detailer, but with the improved protection expected from Meguiar’s Hybrid Ceramic products. It sprays on to lightly clean and protect interior surfaces, leaving a durable, non-greasy, matte finish as well as UV-blocking protection, which is important for surfaces like plastic, vinyl, leather, rubber, and electronic screens. And there’s a great Tropical Citrus scent to keep the interior fresh. The Meguiar’s Hybrid Ceramic Interior Detailer has an MSRP of $12.99.

Hybrid Ceramic Prime Coat Sealant also features Tri-Tech Chemistry and delivers the first-ever spray-and-wipe, dry-applied Sealant to the lineup. Its all-new formula combines the ease of spray-and-wipe sealants on clean exterior surfaces, without the need for water. Its Tri-Tech Chemistry ensures 1) maximum adhesion and 2) maximum longevity for up to six months of protection thanks to advanced polymers. And 3) hydrophobic performance that will shed dirt when used as a foundation layer like a dry applied spray wax. Meguiar’s products such as Hybrid Ceramic Wash, Hybrid Ceramic Detailer and Hybrid Ceramic Wet Wax can then be used to maintain the ceramic properties. The Meguiar’s Hybrid Ceramic Prime Coat Sealant has an MSRP of $21.99. 
Other items in the Meguiar’s Hybrid Ceramic range include Wet Wax, Liquid Wax, Wash & Wax, Waterless Wash & Wax, Detailer and Tire Shine. Full details are available at Meguiar’s.

MEGUIAR’S WHOLE CAR AIR RE-FRESHERS
In an expansion to the collection released at SEMA 2025, Meguiar’s is expanding the range of scents available in the Luxury Collection of its Whole Car Air Re-Freshers. New for 2027 is Tokyo Nights; an invigorating blend of lemon, lime and ginger, which provides a sophisticated and refreshing take on the highly popular “JDM Squash” scent.

Meguiar’s Whole Car Air Re-Freshers are a range of easy, one-time use aerosols. When the cannister is set in the car, its contents are released to quickly fight odors and create a fresh scent that lasts for weeks.

Other scents in the Luxury Collection include Stargazer, Dubai Sands, Tropical Rainforest and Island Volcano. Each Meguiar’s Whole Car Air Re-Fresher has an MSRP of $11.99

MEGUIAR’S HANGING AIR RE-FRESHERS
For the first time, Meguiar’s is introducing a collection of Hanging Air Re-Freshers. They come in two groups: Standard Scents, which take the form of the Meguiar’s “M” logo, and can be purchased in three-packs of either New Car, Black Chrome or Ultimate scents.

The second group consists of the Luxury Collection scents, which includes Stargazer, Dubai Sands, Tropical Rainforest, Island Volcano and Tokyo Nights. The Hanging Air Re-Freshers feature vibrant colors and scenic designs specific to each scent.

Care has been taken to ensure none of the Hanging Air Re-Fresher scents are overpowering. It’s estimated the scent will last approximately 2-4 weeks. A Hanging Air Re-Fresher three-pack has an MSRP of $6.99.

Visitors to the Meguiar’s Indoor and Outdoor SEMA Booths will be able to pick up a sample of the new Air Re-Freshers while stocks last.

MEGUIAR’S ACCESSORIES
With a legacy of 125 years in the car care industry, Meguiar’s has a keen sense of what works and what people really need to keep their cars in prime condition. The Meguiar’s Accessories range is proof there’s a finger on the pulse of car enthusiasts. These new products expand the existing range of special items for individual requirements to help get the job done right.

Meguiar’s Quik Clean Sticky Mitt
Picking up stubborn dust, dirt, crumbs and fur across numerous interior surfaces can be a time-consuming task, but the new Quik Clean Sticky Mitt is designed to remove it all by simply pushing the soft, squishy and sticky wash mitt-shaped accessory into hard to reach nooks and crannies.

Packaged in a mini wash bucket, the non-toxic Sticky Mitt is a fun, scented, sticky-stretchy blob, shaped like a miniature microfiber wash mitt. It collects all the dust and dirt from awkward places on hard surfaces and can be quickly washed off afterwards. The mitt is re-usable for more than 20 times and has an MSRP of only $9.99.

Meguiar’s Quik Pet Hair Remover
The Quik Pet Hair Remover has been designed to assist pet owners who want to tackle stubborn pet hair and fur. The versatile tool has four soft silicone blades with both smooth and gently serrated edges that quickly lift embedded hair from carpets, fabric seats, floor mats, and upholstery. The versatile tool can be used by hand or with a slow-speed hand drill. The Quik Pet Hair Remover is intended for fabrics and not recommended for leather, vinyl, suede, etc. The MSRP is $14.99

Meguiar’s Swirl Stopper Bucket Insert
This item definitely qualifies as IYKYK. The Swirl Stopper Bucket Insert has been engineered with a one-way design that keeps dirt and grime at the bottom of your wash bucket, helping to reduce scratches and swirls during car washing. It’s an ingeniously simple device that fits most 3.5-5-gallon wash buckets thanks to the engineered feet and unique profile. The Swirl Stopper also includes an integrated finger slot for easy placement and removal. The MSRP is $9.99.

Meguiar’s Universal Microfiber Applicator Pads
Designed specifically for the smooth application of conditioners, dressings, protectants and coatings, the Universal Applicator Pads are ideal for use on tires, trim, leather, vinyl and paint. And because the premium microfiber applicators are machine washable, they can be used again and again. The MSRP is $12.99 for a pack of four. (Not recommended for use with compounds, polishes or waxes).

MORE TO COME
Our brief introduction is only scratching the surface of what Meguiar’s has in store for 2027. In the coming months, we’ll provide more information on the aforementioned products as well as the following:

• Meguiar’s Hot Shine Black Plastic Restorer – an expansion to the Hot Shine trim restoration line, it quickly restores textured exterior trim without difficult-to-remove residue. The MSRP is $9.99
• Meguiar’s Wipes – the convenient Wipes line is getting a major makeover with new packaging, expanded to 35 wipes in each larger, round container, and all six applications have the same $8.99 MSRP
• Meguiar’s Professional M111 Heavy Hitter Compound Gel – Containing AMP-Ceramic Abrasives, the innovative, all-new M111 gel-based compound delivers the highest level of cut Meguiar’s has ever offered professional body shops and detailers! It’s packaged in a 16oz bottle with an MSRP of $29.99

SEMA 2026

Throughout SEMA week – from opening day on November 3 to public day on November 6 – the Meguiar’s booths will be a hive of activity. The primary focus will be booth # 22357 in Central Hall. That’s where you’ll find displays of all the new 2027 Meguiar’s car care products, as well as car care experts to explain their benefits. Additionally, Meguiar’s will reveal Tony Peressini’s 1956 Ford F-100 GT/FX from Fat Fender Garage alongside TJ Hunt’s Aston Martin Vantage.

The indoor booth will host autograph sessions on the first two days, where visitors can pick up a signed, limited edition poster from TJ Hunt, Dustin Williams and Fat Fender Garage (while available) at these times:

TJ Hunt	Tuesday 2PM	Meguiar’s booth # 22357
Dustin Williams	Wednesday 10AM	Meguiar’s booth # 22357
Fat Fender Garage	Wednesday 2PM	Meguiar’s booth # 22357

Don’t despair if you miss the posters because Meguiar’s will be handing out Anniversary Cookies and Leen Customs Pins as well as Hanging Air Re-Freshers, lanyards, keychains and totes (while available).

The Meguiar’s Outdoor Booth # 80030 will feature the brand’s famous big rig, which will be the backdrop for more new car reveals including the following:

• Dustin Williams’ Spoon Honda S2000 Turbo
• Pierre Chan’s Datsun 240Z Twin-Turbo widebody
• Gary Stell Jr’s multi award-winning 1951 Mercury
• AR Motorwerkz Porsche 911 GT3 RS

Additionally, the same new products will be on display, and the same giveaways will be available to outdoor visitors (while available), with the exception of the signed posters.

### ENDS ###

EDITOR’S NOTE
Images of the 2027 Meguiar’s products are available here: dropbox.com/scl/fo/arcvc61ktnnnxidl90t29/AOEl5iqzvh6CpYZSGSXetQE?rlkey=wstrimuj46puw0vn28zsvzu23&dl=0

Attachments

• Meguiar’s® announces its 2027 Car Care Products
• Meguiar’s® announces its 2027 Car Care Products

CONTACT: Blake Beamish
Meguiar's, Inc
bbeamish@meguiars.com

MOLINE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (Nasdaq: QCRH) (the “Company”) today announced that its subsidiary, Cedar Rapids Bank & Trust Company, has entered into a definitive agreement with BankIowa, based in Cedar Rapids, Iowa, to sell its Community Bank & Trust division, which consists of three branch locations serving the Waterloo-Cedar Falls metropolitan area.

The transaction includes two branches located in Waterloo, Iowa, and one branch located in Cedar Falls, Iowa. The sale includes certain deposits and loans associated with the three branches, totaling approximately $140 million and $29 million, respectively, as of September 30, 2026. Certain wealth management relationships associated with customers in the market are also expected to transition as part of the transaction, representing approximately $153 million in assets under management as of September 30, 2026.

“This transaction reflects our ongoing commitment to strategically allocate resources and optimize our Company for sustained top-tier financial performance,” said Todd A. Gipple, President and CEO of the Company. “While we are grateful for the relationships our team has built in the Waterloo and Cedar Falls markets, we believe this transaction provides the best opportunity for these clients, employees, and communities, while allowing us to sharpen our focus on markets where we see the greatest long-term growth potential.”

“We are excited to welcome these clients and employees to BankIowa,” said Alison Urbina, President and CEO of BankIowa. “This transaction strengthens our presence in the Cedar Valley market and aligns with our commitment to deliver exceptional service and support to the individuals, families, and businesses in the area.”

The transaction is not expected to result in a material gain or loss to the Company and is anticipated to close during the first quarter of 2027, subject to customary closing conditions and regulatory approvals.

Clients of Community Bank & Trust will continue to be served through their existing branch locations and will receive additional information regarding account and service transitions prior to closing.

“We are committed to ensuring a seamless transition for our clients and employees. We appreciate the trust our Waterloo and Cedar Falls clients have placed in us over the years, and we are confident they will continue to receive outstanding local community-based service from BankIowa,” Gipple added.

About Us
QCR Holdings, Inc., headquartered in Moline, Illinois, is a relationship-driven, multi-bank holding company serving the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny and Springfield communities through its wholly owned subsidiary banks. The banks provide full-service commercial and consumer banking and trust and wealth management services. Quad City Bank & Trust Company, based in Bettendorf, Iowa, commenced operations in 1994, Cedar Rapids Bank & Trust Company, based in Cedar Rapids, Iowa, commenced operations in 2001, Community State Bank, based in Ankeny, Iowa, was acquired by the Company in 2016, and Guaranty Bank, based in Springfield, Missouri, was acquired by the Company in 2018. Additionally, the Company serves the Waterloo/Cedar Falls, Iowa community through Community Bank & Trust, a division of Cedar Rapids Bank & Trust Company. The Company has 35 locations in Iowa, Missouri, and Illinois. As of September 30, 2026, the Company had $9.8 billion in assets, $7.2 billion in loans and $7.2 billion in deposits. For additional information, please visit the Company’s website at www.qcrh.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated closing of the transaction, regulatory approvals, expected financial impact and other future events. Actual results may differ materially from those indicated in such statements due to various risks and uncertainties. Readers are encouraged to review QCR Holdings, Inc.’s filings with the Securities and Exchange Commission for additional information regarding factors that could affect future results.

Contact:
Doug Neumann
VP, Investor Relations
(309) 743-7753
dneumann@qcrh.com

MOLINE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (Nasdaq: QCRH) (the “Company”) today announced that its subsidiary, Cedar Rapids Bank & Trust Company, has entered into a definitive agreement with BankIowa, based in Cedar Rapids, Iowa, to sell its Community Bank & Trust division, which consists of three branch locations serving the Waterloo-Cedar Falls metropolitan area.

The transaction includes two branches located in Waterloo, Iowa, and one branch located in Cedar Falls, Iowa. The sale includes certain deposits and loans associated with the three branches, totaling approximately $140 million and $29 million, respectively, as of September 30, 2026. Certain wealth management relationships associated with customers in the market are also expected to transition as part of the transaction, representing approximately $153 million in assets under management as of September 30, 2026.

“This transaction reflects our ongoing commitment to strategically allocate resources and optimize our Company for sustained top-tier financial performance,” said Todd A. Gipple, President and CEO of the Company. “While we are grateful for the relationships our team has built in the Waterloo and Cedar Falls markets, we believe this transaction provides the best opportunity for these clients, employees, and communities, while allowing us to sharpen our focus on markets where we see the greatest long-term growth potential.”

“We are excited to welcome these clients and employees to BankIowa,” said Alison Urbina, President and CEO of BankIowa. “This transaction strengthens our presence in the Cedar Valley market and aligns with our commitment to deliver exceptional service and support to the individuals, families, and businesses in the area.”

The transaction is not expected to result in a material gain or loss to the Company and is anticipated to close during the first quarter of 2027, subject to customary closing conditions and regulatory approvals.

Clients of Community Bank & Trust will continue to be served through their existing branch locations and will receive additional information regarding account and service transitions prior to closing.

“We are committed to ensuring a seamless transition for our clients and employees. We appreciate the trust our Waterloo and Cedar Falls clients have placed in us over the years, and we are confident they will continue to receive outstanding local community-based service from BankIowa,” Gipple added.

About Us
QCR Holdings, Inc., headquartered in Moline, Illinois, is a relationship-driven, multi-bank holding company serving the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny and Springfield communities through its wholly owned subsidiary banks. The banks provide full-service commercial and consumer banking and trust and wealth management services. Quad City Bank & Trust Company, based in Bettendorf, Iowa, commenced operations in 1994, Cedar Rapids Bank & Trust Company, based in Cedar Rapids, Iowa, commenced operations in 2001, Community State Bank, based in Ankeny, Iowa, was acquired by the Company in 2016, and Guaranty Bank, based in Springfield, Missouri, was acquired by the Company in 2018. Additionally, the Company serves the Waterloo/Cedar Falls, Iowa community through Community Bank & Trust, a division of Cedar Rapids Bank & Trust Company. The Company has 35 locations in Iowa, Missouri, and Illinois. As of September 30, 2026, the Company had $9.8 billion in assets, $7.2 billion in loans and $7.2 billion in deposits. For additional information, please visit the Company’s website at www.qcrh.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated closing of the transaction, regulatory approvals, expected financial impact and other future events. Actual results may differ materially from those indicated in such statements due to various risks and uncertainties. Readers are encouraged to review QCR Holdings, Inc.’s filings with the Securities and Exchange Commission for additional information regarding factors that could affect future results.

Contact:
Doug Neumann
VP, Investor Relations
(309) 743-7753
dneumann@qcrh.com

MOLINE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (Nasdaq: QCRH) (the “Company”) today announced that its subsidiary, Cedar Rapids Bank & Trust Company, has entered into a definitive agreement with BankIowa, based in Cedar Rapids, Iowa, to sell its Community Bank & Trust division, which consists of three branch locations serving the Waterloo-Cedar Falls metropolitan area.

The transaction includes two branches located in Waterloo, Iowa, and one branch located in Cedar Falls, Iowa. The sale includes certain deposits and loans associated with the three branches, totaling approximately $140 million and $29 million, respectively, as of September 30, 2026. Certain wealth management relationships associated with customers in the market are also expected to transition as part of the transaction, representing approximately $153 million in assets under management as of September 30, 2026.

“This transaction reflects our ongoing commitment to strategically allocate resources and optimize our Company for sustained top-tier financial performance,” said Todd A. Gipple, President and CEO of the Company. “While we are grateful for the relationships our team has built in the Waterloo and Cedar Falls markets, we believe this transaction provides the best opportunity for these clients, employees, and communities, while allowing us to sharpen our focus on markets where we see the greatest long-term growth potential.”

“We are excited to welcome these clients and employees to BankIowa,” said Alison Urbina, President and CEO of BankIowa. “This transaction strengthens our presence in the Cedar Valley market and aligns with our commitment to deliver exceptional service and support to the individuals, families, and businesses in the area.”

The transaction is not expected to result in a material gain or loss to the Company and is anticipated to close during the first quarter of 2027, subject to customary closing conditions and regulatory approvals.

Clients of Community Bank & Trust will continue to be served through their existing branch locations and will receive additional information regarding account and service transitions prior to closing.

“We are committed to ensuring a seamless transition for our clients and employees. We appreciate the trust our Waterloo and Cedar Falls clients have placed in us over the years, and we are confident they will continue to receive outstanding local community-based service from BankIowa,” Gipple added.

About Us
QCR Holdings, Inc., headquartered in Moline, Illinois, is a relationship-driven, multi-bank holding company serving the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny and Springfield communities through its wholly owned subsidiary banks. The banks provide full-service commercial and consumer banking and trust and wealth management services. Quad City Bank & Trust Company, based in Bettendorf, Iowa, commenced operations in 1994, Cedar Rapids Bank & Trust Company, based in Cedar Rapids, Iowa, commenced operations in 2001, Community State Bank, based in Ankeny, Iowa, was acquired by the Company in 2016, and Guaranty Bank, based in Springfield, Missouri, was acquired by the Company in 2018. Additionally, the Company serves the Waterloo/Cedar Falls, Iowa community through Community Bank & Trust, a division of Cedar Rapids Bank & Trust Company. The Company has 35 locations in Iowa, Missouri, and Illinois. As of September 30, 2026, the Company had $9.8 billion in assets, $7.2 billion in loans and $7.2 billion in deposits. For additional information, please visit the Company’s website at www.qcrh.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated closing of the transaction, regulatory approvals, expected financial impact and other future events. Actual results may differ materially from those indicated in such statements due to various risks and uncertainties. Readers are encouraged to review QCR Holdings, Inc.’s filings with the Securities and Exchange Commission for additional information regarding factors that could affect future results.

Contact:
Doug Neumann
VP, Investor Relations
(309) 743-7753
dneumann@qcrh.com

To Nasdaq Copenhagen A/S 

                                                                                       2 November 2026
                                                                                       Announcement no. 93/2026

Jyske Realkredit’s auctions for 1 January 2027 refinancing

Jyske Realkredit plans to carry out the auction from Monday 16^th to Thursday 19^th of November 2026 for loans in cover pool E.

The refinancing amount and bonds to be offered are specified in the table below:

	Open	Close	Alloc.	Name	ISIN	Amount mill.	LCR
Monday 16 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Tuesday 17 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Wednesday 18 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Thursday 19 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B

Auction terms appear in the appendix.

Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of Realkredit Treasury tel. (+45) 89 89 92 19 or Christian Bech-Ravn, Director, Head of Investor Relations, tel. (+45) 89 89 92 25.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Appendix – Auctions terms

Refinancing principles adjustable rate mortgage loans
Jyske Realkredit offers fixed-rate non-callable bonds for adjusting interest rates on the loans.

When adjusting the interest rates, the bonds are sold at one or more auctions. The price is determined as a weighted average of the prices obtained at the auctions.

Type of auction
The auction of bonds in capital centres E will be conducted on Bloomberg’s auction system.

Bids
Bids for the offered bonds must be made in terms of amount and price.

For bonds maturing within 14 months, bids must be made correct to three decimals. For other bonds, bids must be made with an accuracy of two decimals.

For all bonds bids must be made in multiples of DKK 1,000,000

Conditional offer for bonds with interest rate triggers
For the bonds offered with an interest rate trigger, it is a condition for the final completion of the sale (allotment) that there is no increase in interest rates of more than 5 percentage points. Reference is made to the Act on Mortgage Loans and Mortgage Bonds, etc.

Allotment
All bids above the cut-off price will be settled in full at the cut-off fixing spread. For bids at the exact cut-off price, proportional allocation may be used. No bids below the cut-off price will be settled.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auction will take place as soon as possible, and not later than 5 minutes after closing.

Value date
All bonds will be subject to long settlement. The value date of all trades executed at the auction will be 1^st of January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Jyske Realkredit offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two days.

By means of the reverse facility, Jyske Realkredit offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 1^st of January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder.

The reverse facility can be made conditional on the investor providing a corresponding amount of Jyske Realkredit covered bonds (SDO) or mortgage bonds (RO) maturing on 1^st of January 2027 or a corresponding amount of DKK SDO/SDRO level 1B AAA rated covered bonds issued from other Danish mortgage institutions maturing on 1st of January 2027.

Reverse facilities will be arranged on an individual basis by contacting Jyske Realkredit

Credit Ratings
All auctioned bonds issued through Capital Centre E are rated AAA by S&P.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Jyske Realkredit from conducting an auction through Bloombergs auction system, a stock ex-change announcement will be issued containing the practical details of the auction.

Other terms
Jyske Realkredit is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

To Nasdaq Copenhagen A/S 

                                                                                       2 November 2026
                                                                                       Announcement no. 93/2026

Jyske Realkredit’s auctions for 1 January 2027 refinancing

Jyske Realkredit plans to carry out the auction from Monday 16^th to Thursday 19^th of November 2026 for loans in cover pool E.

The refinancing amount and bonds to be offered are specified in the table below:

	Open	Close	Alloc.	Name	ISIN	Amount mill.	LCR
Monday 16 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Tuesday 17 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Wednesday 18 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Thursday 19 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B

Auction terms appear in the appendix.

Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of Realkredit Treasury tel. (+45) 89 89 92 19 or Christian Bech-Ravn, Director, Head of Investor Relations, tel. (+45) 89 89 92 25.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Appendix – Auctions terms

Refinancing principles adjustable rate mortgage loans
Jyske Realkredit offers fixed-rate non-callable bonds for adjusting interest rates on the loans.

When adjusting the interest rates, the bonds are sold at one or more auctions. The price is determined as a weighted average of the prices obtained at the auctions.

Type of auction
The auction of bonds in capital centres E will be conducted on Bloomberg’s auction system.

Bids
Bids for the offered bonds must be made in terms of amount and price.

For bonds maturing within 14 months, bids must be made correct to three decimals. For other bonds, bids must be made with an accuracy of two decimals.

For all bonds bids must be made in multiples of DKK 1,000,000

Conditional offer for bonds with interest rate triggers
For the bonds offered with an interest rate trigger, it is a condition for the final completion of the sale (allotment) that there is no increase in interest rates of more than 5 percentage points. Reference is made to the Act on Mortgage Loans and Mortgage Bonds, etc.

Allotment
All bids above the cut-off price will be settled in full at the cut-off fixing spread. For bids at the exact cut-off price, proportional allocation may be used. No bids below the cut-off price will be settled.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auction will take place as soon as possible, and not later than 5 minutes after closing.

Value date
All bonds will be subject to long settlement. The value date of all trades executed at the auction will be 1^st of January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Jyske Realkredit offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two days.

By means of the reverse facility, Jyske Realkredit offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 1^st of January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder.

The reverse facility can be made conditional on the investor providing a corresponding amount of Jyske Realkredit covered bonds (SDO) or mortgage bonds (RO) maturing on 1^st of January 2027 or a corresponding amount of DKK SDO/SDRO level 1B AAA rated covered bonds issued from other Danish mortgage institutions maturing on 1st of January 2027.

Reverse facilities will be arranged on an individual basis by contacting Jyske Realkredit

Credit Ratings
All auctioned bonds issued through Capital Centre E are rated AAA by S&P.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Jyske Realkredit from conducting an auction through Bloombergs auction system, a stock ex-change announcement will be issued containing the practical details of the auction.

Other terms
Jyske Realkredit is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

To Nasdaq Copenhagen A/S 

                                                                                       2 November 2026
                                                                                       Announcement no. 93/2026

Jyske Realkredit’s auctions for 1 January 2027 refinancing

Jyske Realkredit plans to carry out the auction from Monday 16^th to Thursday 19^th of November 2026 for loans in cover pool E.

The refinancing amount and bonds to be offered are specified in the table below:

	Open	Close	Alloc.	Name	ISIN	Amount mill.	LCR
Monday 16 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Tuesday 17 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Wednesday 18 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Thursday 19 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B

Auction terms appear in the appendix.

Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of Realkredit Treasury tel. (+45) 89 89 92 19 or Christian Bech-Ravn, Director, Head of Investor Relations, tel. (+45) 89 89 92 25.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Appendix – Auctions terms

Refinancing principles adjustable rate mortgage loans
Jyske Realkredit offers fixed-rate non-callable bonds for adjusting interest rates on the loans.

When adjusting the interest rates, the bonds are sold at one or more auctions. The price is determined as a weighted average of the prices obtained at the auctions.

Type of auction
The auction of bonds in capital centres E will be conducted on Bloomberg’s auction system.

Bids
Bids for the offered bonds must be made in terms of amount and price.

For bonds maturing within 14 months, bids must be made correct to three decimals. For other bonds, bids must be made with an accuracy of two decimals.

For all bonds bids must be made in multiples of DKK 1,000,000

Conditional offer for bonds with interest rate triggers
For the bonds offered with an interest rate trigger, it is a condition for the final completion of the sale (allotment) that there is no increase in interest rates of more than 5 percentage points. Reference is made to the Act on Mortgage Loans and Mortgage Bonds, etc.

Allotment
All bids above the cut-off price will be settled in full at the cut-off fixing spread. For bids at the exact cut-off price, proportional allocation may be used. No bids below the cut-off price will be settled.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auction will take place as soon as possible, and not later than 5 minutes after closing.

Value date
All bonds will be subject to long settlement. The value date of all trades executed at the auction will be 1^st of January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Jyske Realkredit offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two days.

By means of the reverse facility, Jyske Realkredit offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 1^st of January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder.

The reverse facility can be made conditional on the investor providing a corresponding amount of Jyske Realkredit covered bonds (SDO) or mortgage bonds (RO) maturing on 1^st of January 2027 or a corresponding amount of DKK SDO/SDRO level 1B AAA rated covered bonds issued from other Danish mortgage institutions maturing on 1st of January 2027.

Reverse facilities will be arranged on an individual basis by contacting Jyske Realkredit

Credit Ratings
All auctioned bonds issued through Capital Centre E are rated AAA by S&P.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Jyske Realkredit from conducting an auction through Bloombergs auction system, a stock ex-change announcement will be issued containing the practical details of the auction.

Other terms
Jyske Realkredit is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.

• Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline
• Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities
• Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) — Supernus, Inc. (Nasdaq: SUPN)¹ today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus, Inc. Creates Immediate Scale and Expanded Capabilities

• A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE^®, Qelbree^®, GOCOVRI^®, ONAPGO^®, and ZURZUVAE^® – that provide a durable foundation for long-term revenue expansion.
• Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.

“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”

Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, “This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value.”

The Merger and Transaction Details
Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.

Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.

Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.

Leadership and Governance
Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company’s Board of Directors has a total of eight directors, including four directors from each of the legacy companies.

Advisors
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.

Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.

Additional information about the transaction can be found on the Supernus website, which is listed below.

About Supernus, Inc.
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.

Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.

For more information, please visit www.supernus.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements are based on Supernus’s current expectations, estimates, and assumptions and are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., including anticipated synergies, cost savings, enhanced cash flow, financial flexibility, and scale, and the timeframe for realizing them; the combined company’s positioning as a leading diversified central nervous system (CNS) biopharmaceutical company; the expectation that the combined company’s common stock will begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026, and the related delisting and relisting; the expected performance of the combined company’s 11-product portfolio and the potential of its five core growth drivers to provide a durable foundation for long-term revenue expansion; the combined company’s plans and capacity to advance its CNS pipeline, pursue strategic growth opportunities and future business development, and allocate capital in a disciplined manner to create shareholder value; the integration of the legacy Supernus and Indivior businesses; the timing and progress of clinical trials and the receipt and timing of regulatory approvals; the expansion of manufacturing capabilities, including manufacture of ONAPGO at a second supplier; and the combined company’s future financial performance and projected expenditures. Forward-looking statements also include any other statements that are not statements of historical fact, including those that use words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “outlook,” “forecast,” “guidance,” “may,” “will,” “would,” “could,” “should,” and similar expressions, although not all forward-looking statements contain these words.

All forward-looking statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that the anticipated benefits, synergies, and cost savings of the merger may not be realized within the expected timeframe or at all; the difficulties and costs of integrating the legacy businesses of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and the risk that the integration may divert management attention or disrupt operations or relationships with customers, payors, suppliers, or employees; the effect of the combined company’s indebtedness, including the term loan facility used to fund the special cash dividend, on its financial results; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for, and net revenue from, each of its products and the products of its subsidiaries, and to commercialize those products; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates or to manufacture ONAPGO at the second supplier; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and to operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state, and foreign regulatory requirements; the therapeutic benefits, effectiveness, and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products, including ONAPGO, and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs; and the other risks identified in the Company’s filings with the SEC.

These forward-looking statements speak only as of the date of this press release, and Supernus, Inc. undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

End note

(1) As part of the closing process, Supernus Pharmaceuticals, Inc. will be delisted from Nasdaq. The combined company, Supernus, Inc., is expected to trade under the ticker symbol SUPN beginning on November 3, 2026. The combined company, Supernus, Inc., will trade under the ticker symbol INDV on November 2, 2026.

Supernus, Inc. Contacts

Investors
Peter Vozzo 
ICR Healthcare 
+1 443 213 0505
peter.vozzo@icrhealthcare.com
     
Media
mediacontacts@supernus.com

• Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline
• Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunities
• Combined entity will operate as Supernus, Inc. and begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) — Supernus, Inc. (Nasdaq: SUPN)¹ today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus, Inc. Creates Immediate Scale and Expanded Capabilities

• A Diversified Commercial Platform: An 11-product portfolio spans opioid use disorder, psychiatry, and neurology, and includes five core growth drivers – SUBLOCADE^®, Qelbree^®, GOCOVRI^®, ONAPGO^®, and ZURZUVAE^® – that provide a durable foundation for long-term revenue expansion.
• Established Financial Scale and Enhanced Cash Flow: Financial capacity to pursue further growth opportunities, including driving growth in its commercial portfolio, advancing its novel pipeline, and pursuing future business.

“Today marks a transformative milestone as we officially bring together two organizations united by a shared dedication to those living with complex neurological conditions,” said Jack Khattar, President and CEO of Supernus, Inc. “As one team, we are committed to expanding meaningful treatments for patients, executing seamlessly, and delivering long-term value for our shareholders.”

Tony Kingsley, Chair of the Board of Directors of Supernus, Inc., added, “This combination brings together best-in-class commercial capabilities, leading CNS therapies, and a strong financial foundation. We believe the combined company is exceptionally well positioned to pursue long-term growth while maintaining disciplined capital allocation and a commitment to creating shareholder value.”

The Merger and Transaction Details
Under the terms of the definitive merger agreement, Supernus Pharmaceuticals, Inc. stockholders received 1.5401 common shares of Indivior Pharmaceuticals, Inc. for each share of Supernus Pharmaceuticals, Inc. they owned.

Stockholders of Indivior immediately prior to the closing of the merger will receive a one-time special cash dividend of $1.0 billion in the aggregate as previously announced. To finance the dividend to Indivior stockholders, the companies utilized a previously secured debt commitment of $650 million through a term loan facility provided by Citibank N.A., with the remaining portion funded by existing cash on hand of the combined company.

Upon the close of the transaction, former Indivior stockholders own approximately 56.5% of the combined company, and former Supernus Pharmaceuticals, Inc. stockholders own approximately 43.5% of the combined company, on a fully diluted basis.

Leadership and Governance
Supernus Pharmaceuticals’ current headquarters in Rockville, Md., will serve as the combined company’s global headquarters. Jack Khattar will serve as President, Chief Executive Officer and a member of the Board of Directors of the combined company, and Tony Kingsley, previously a member of Indivior’s Board of Directors, will serve as Board Chair. The combined company’s Board of Directors has a total of eight directors, including four directors from each of the legacy companies.

Advisors
Cantor Fitzgerald & Co. served as lead financial advisor to Supernus Pharmaceuticals. Wells Fargo also served as an additional financial advisor to Supernus Pharmaceuticals. Saul Ewing LLP served as legal counsel to Supernus Pharmaceuticals and Morgan Lewis UK served as legal advisors to Supernus Pharmaceuticals with respect to certain ex-US matters.

Jefferies LLC and Piper Sandler & Co. served as joint financial advisors to Indivior and Goodwin Procter LLP served as legal counsel to Indivior. Citi also provided financial advice to Indivior, and Citibank, N.A. provided committed financing in support of the transaction.

Additional information about the transaction can be found on the Supernus website, which is listed below.

About Supernus, Inc.
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases.

Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.

For more information, please visit www.supernus.com.

Forward-Looking Statements
This press release contains forward-looking statements. These statements are based on Supernus’s current expectations, estimates, and assumptions and are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding: the expected benefits of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., including anticipated synergies, cost savings, enhanced cash flow, financial flexibility, and scale, and the timeframe for realizing them; the combined company’s positioning as a leading diversified central nervous system (CNS) biopharmaceutical company; the expectation that the combined company’s common stock will begin trading on the Nasdaq Global Market under the ticker symbol “SUPN” on November 3, 2026, and the related delisting and relisting; the expected performance of the combined company’s 11-product portfolio and the potential of its five core growth drivers to provide a durable foundation for long-term revenue expansion; the combined company’s plans and capacity to advance its CNS pipeline, pursue strategic growth opportunities and future business development, and allocate capital in a disciplined manner to create shareholder value; the integration of the legacy Supernus and Indivior businesses; the timing and progress of clinical trials and the receipt and timing of regulatory approvals; the expansion of manufacturing capabilities, including manufacture of ONAPGO at a second supplier; and the combined company’s future financial performance and projected expenditures. Forward-looking statements also include any other statements that are not statements of historical fact, including those that use words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “project,” “target,” “outlook,” “forecast,” “guidance,” “may,” “will,” “would,” “could,” “should,” and similar expressions, although not all forward-looking statements contain these words.

All forward-looking statements involve risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to: the risk that the anticipated benefits, synergies, and cost savings of the merger may not be realized within the expected timeframe or at all; the difficulties and costs of integrating the legacy businesses of Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc., and the risk that the integration may divert management attention or disrupt operations or relationships with customers, payors, suppliers, or employees; the effect of the combined company’s indebtedness, including the term loan facility used to fund the special cash dividend, on its financial results; the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for, and net revenue from, each of its products and the products of its subsidiaries, and to commercialize those products; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates or to manufacture ONAPGO at the second supplier; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and to operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state, and foreign regulatory requirements; the therapeutic benefits, effectiveness, and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products, including ONAPGO, and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; changes to laws and regulations applicable to our industry; the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes, and tariffs; and the other risks identified in the Company’s filings with the SEC.

These forward-looking statements speak only as of the date of this press release, and Supernus, Inc. undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by applicable law.

End note

(1) As part of the closing process, Supernus Pharmaceuticals, Inc. will be delisted from Nasdaq. The combined company, Supernus, Inc., is expected to trade under the ticker symbol SUPN beginning on November 3, 2026. The combined company, Supernus, Inc., will trade under the ticker symbol INDV on November 2, 2026.

Supernus, Inc. Contacts

Investors
Peter Vozzo 
ICR Healthcare 
+1 443 213 0505
peter.vozzo@icrhealthcare.com
     
Media
mediacontacts@supernus.com